Richard is the founder and managing director of XenoGesis, an independent laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation.
Having joined Astra Charnwood in 1997 within Discovery DMPK, Richard progressed to Group and Project Leader at AstraZeneca. During that time Richard gained and developed an in-depth knowledge of all aspects of In vitro and In vivo Drug Metabolism and Pharmacokinetics from Hit Identification to Candidate Drug nomination and beyond.
In 2011, Richard spotted an opportunity in the market and set up XenoGesis. His clear direction, vision and entrepreneurial approach to running a business has seen XenoGesis expand from 3 to 22 employees in just under five years, as well as now supporting over 100 companies and Universities around the world. His ambition is to build on this growth in the coming years whilst focusing on the XenoGesis reputation of providing a consultative approach to preclinical DMPK, TK and Bioanalysis projects to help clients achieve their drug discovery goals.
Richard gained a first class honours degree in chemistry with awards for the best performance in every year, followed by a medicinal chemistry PhD with a Wellcome Trust scholarship at the University of Leicester and two subsequent postdoctoral positions at the Welsh School of Pharmacy. He has authored and co-authored twenty one publications to date and in 2014, Richard was invited to become a Fellow of the Royal Society of Chemistry.